Terns Pharmaceuticals, Inc. (TERN) stock is soaring 5.23% in pre-market trading on Tuesday, buoyed by a series of positive analyst actions. The healthcare company has received multiple buy ratings and increased price targets from prominent financial institutions, signaling strong confidence in its future prospects.

Mizuho Securities has reaffirmed its Buy rating on Terns Pharmaceuticals, setting an ambitious price target of $32.00. Meanwhile, Barclays has raised its target price for TERN from $27 to $28, while also maintaining a Buy rating. These upgrades come as part of a broader positive sentiment towards the healthcare sector, with analysts offering insights on several companies including Terns Pharmaceuticals.

The surge in Terns Pharmaceuticals' stock price reflects investors' optimism following these analyst reports. The maintained Buy ratings and increased price targets suggest that financial experts see significant growth potential in the company's pipeline and business strategy. As the healthcare sector continues to attract attention, Terns Pharmaceuticals appears well-positioned to capitalize on market opportunities, potentially driving further stock appreciation in the near future.